Daniel Tietjen is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. His focus is on litigation and legal advice to national and international companies, particularly in all areas of pharmaceutical law, medical device law, unfair competition law and intellectual property law including trademark law.
Possible ban on the mail-order of prescription-only (Rx) medicinal products in Germany, Dr. Daniel Tietjen, March 2018
Software als Medizinprodukt, Dr. Daniel Tietjen, Zeitschrift für Stoffrecht Jahrgang 15, Ausgabe 1 (2018) pp. 19 - 21
Dynamische und personalisierte Preise: Welche lauterkeitsrechtlichen Schranken gelten für Unternehmen?, in: GRUR-Prax 2017, 546 (zusammen mit Dr. Benedikt F. Flöter)
„Das System des gemeinschaftsrechtlichen Staatshaftungsrechts“, Duncker & Humblot, Berlin, 2010
„Die Bedeutung der deutschen Richterprivilegien im System des gemeinschaftsrechtlichen Staatshaftungsrechts“, EWS 2007, 15
Recommended lawyer for Healthcare and life sciences
Years of working in the life sciences industry have led to a great deal of experience and industry knowledge, which ensures not only legally competent but also strategically helpful support for our projects.
Frequently recommended lawyer for healthcare - Hospitals, MVZs and pharmacies
Frequently recommended lawyer for pharmaceutical and medical product law
Law firm of the year for IP Law
Leading individual: Competition / Antitrust Law
Recommended lawyer: Healthcare and life sciences
"Daniel Tietjen has excellent knowledge of competition law, in particular the law on the advertising of medicinal products, and regularly supports us in this area. I very much appreciate his practical and creative approach to finding solutions."
"Daniel Tietjen always reacts quickly, works very conscientiously and is always very solution-oriented."
Leading individual: Competition / Antitrust Law
Leading individual: Antitrust and competition law
Leading individual: Competition / Antitrust Law
Leading individual for health law
NORD Holding, a leading private equity house, on the acquisition of the majority interest in Zentrum Gesundheit Group, a leading German group of ophthalmic surgery and diagnostic centres, from Waterland Private Equity. NORD Holding, together with the management and medical team, acquired a stake as a new partner and majority shareholder. In this deal the Taylor Wessing team again demonstrated its interdisciplinary expertise in the areas of healthcare M&A, regulatory and acquisition financing.
Press releaseRegional Court of Bochum: Request for a preliminary ruling to the CJEU – Are blank patient wristbands for hospital use considered medical devices?
Federal Court of Justice: "Gentle on the skin" is misleading advertising for biocidal products
作者 Katie Chandler 以及 Helen Brannigan
作者